Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Income from Continuing Operations (2016 - 2025)

Sangamo Therapeutics (SGMO) has 16 years of Income from Continuing Operations data on record, last reported at 34930000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 427.31% year-over-year to 34930000.0; the TTM value through Sep 2025 reached 108909000.0, up 19.23%, while the annual FY2024 figure was 97941000.0, 62.01% up from the prior year.
  • Income from Continuing Operations reached 34930000.0 in Q3 2025 per SGMO's latest filing, down from 19986000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 21133000.0 in Q1 2023 and bottomed at 114470000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 42729210.53, with a median of 43977000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: crashed 3062.33% in 2021, then soared 148.05% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 37496000.0 in 2021, then tumbled by 38.53% to 51943000.0 in 2022, then fell by 16.08% to 60295000.0 in 2023, then soared by 61.2% to 23396000.0 in 2024, then plummeted by 49.3% to 34930000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 34930000.0 in Q3 2025, 19986000.0 in Q2 2025, and 30597000.0 in Q1 2025.